ARCHIVES

Program Project Scores Have Compressed Review Shuld Return To Rank Order; Broder

This article is from The Cancer Letter archive.

Vol. 18 No. 38 | October 2, 1992

Download PDF Visit The Full Archive

Related Articles

Safety Concerns About Saltz Regimen Were Statistical Artifact, ODAC Finds.

December 14, 2001

Lilly Suspends Phase III Trial Of Tasisulam in Melanoma

January 28, 2011

In Brief: AC Committee Picks Seffrin for Executive VP; Charles Wilson Names to NCAB; 5 Leave Board

May 15, 1992

ASA Honors Bernard Fisher With Surgeons’ Highest Award.

April 21, 2000

October issue of Business & Regulatory Report (8-page issue).

November 2, 2002

Vaccine Increases PFS 146%, OS 60% In Phase II Clinical Trial

May 31, 2013